Marijuana receptor caught in the act | July 10, 2017 Issue - Vol. 95 Issue 28 | Chemical & Engineering News
Volume 95 Issue 28 | p. 9 | News of The Week
Issue Date: July 10, 2017 | Web Date: July 7, 2017

Marijuana receptor caught in the act

High-resolution X-ray structures of a cannabinoid receptor with activating agents help reveal how it works
Department: Science & Technology
Keywords: structural biology, cannabinoid receptor, CB╩1╩, marijuana, Δ╔9╔-THC, X-ray crystal structures
[+]Enlarge
Superimposed crystal structures of CB1 (ribbon structure and orange surface outline) with tetrahydrocannabinol and hexahydrocannabinol activating agents in the receptor’s binding pocket.
Credit: Nature
Superimposed crystal structures of activated CB<sub>1</sub>, with tetrahydrocannabinol  and hexahydrocannabinol agonists bound to the receptor’s binding site.
 
Superimposed crystal structures of CB1 (ribbon structure and orange surface outline) with tetrahydrocannabinol and hexahydrocannabinol activating agents in the receptor’s binding pocket.
Credit: Nature

Marijuana has been used both recreationally and as a drug for centuries, has been banned in many countries for decades, and has recently been legalized in some U.S. states. But researchers haven’t been able to get a high-resolution look at the way its active component, Δ9-tetrahydrocannabinol (Δ9-THC), interacts with its principal protein receptor in the body, cannabinoid receptor 1 (CB1).

CB1 is a G protein-coupled receptor found mostly in central nervous system cell membranes. Last year, two groups managed to capture structures of CB1 bound to inhibitors and in a “switched off” state. Activated receptors break down more easily when manipulated, so they are harder to crystallize and analyze structurally.

Now, one of the same groups—including Zhi-Jie Liu and Suwen Zhao of ShanghaiTech University, Laura M. Bohn of Scripps Research Institute Florida, and Alexandros Makriyannis of Northeastern University—has obtained high-resolution X-ray crystal structures of the receptor bound to two hydrocannabinol activating agents (Nature 2017, DOI: 10.1038/nature23272). The study, which reveals how agents such as Δ9-THC “turn on” CB1, could help researchers design a new generation of safer therapeutics.

“CB1 is a highly valued drug target for obesity, pain, fibrosis, and nonalcoholic steatohepatitis,” but current drugs that hit the receptor have serious side effects, Liu says.

The researchers obtained the new structures by designing and synthesizing two hydrocannabinols that resemble Δ9-THC but bind CB1 with higher affinity, and by modifying four of the receptor’s amino acid residues to enhance its stability.

Compared with the inactivated receptor, activated CB1 has a binding pocket 53% smaller in volume. It also has a twin toggle switch—two residues whose positions change to accommodate and promote agonist binding and receptor activation—and a larger surface area for binding G proteins.

Debra Kendall, an expert on cannabinoid receptor activation and signal transduction at the University of Connecticut School of Pharmacy, comments that she is “strongly positive” about the significance of the findings, noting that the determination of activated structures and their comparison with inhibitor-bound forms provide substantial detail on the mechanism of activation that could aid the design of novel CB1-targeted drug candidates.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment